Pulse Journal Club Active Debates Trending Explore Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Home Explore Journal Club Trending

⌘+K

Sugammadex: clinical development and practical use | Synapse

January 1, 2013Open Access

Sugammadex: clinical development and practical use

Key Points

Key points are not available for this paper at this time.

Abstract

the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine.

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Fuchs‐Buder et al. (Tue,) studied this question.

synapsesocial.com/papers/69d89dd1a5ecc596b5d17e89 https://doi.org/https://doi.org/10.4097/kjae.2013.65.6.495

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical Patients2009 · 204 citations
2A Randomized, Dose-Response Study of Sugammadex Given for the Reversal of Deep Rocuronium- or Vecuronium-Induced Neuromuscular Blockade Under Sevoflurane Anesthesia2009 · 149 citations
3Effect of an Intubating Dose of Succinylcholine and Atracurium on the Diaphragm and the Adductor Pollicis Muscle in Humans1987 · 111 citations
4A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host The discovery of Org 25969 is the result of teamwork with contributions from a number of scientists both inside Organon and outside the company. We would like in particular to acknowledge the following scientists for their invaluable contributions: E. Hutchinson, D. Stevenson, R. Roy, and J. Pick for scaling-up the synthesis; F. Hope, S. Miller, and R. Mason for various in vitro and in vivo pharmacological testing; R. Watson, B. Montgomery, P. Desmond, and A. Osprey for all their analytical effort; and R. McGuire and J. Mestres for graphical presentation of the X-ray crystal structure of the Org 25969–rocuronium complex (Figure 3). We would also like to thank Prof. A. Cooper of Glasgow University who has critically reproduced our calorimetry data of Org 25969–rocuronium complexation (Figure 2).2002 · 457 citations
5Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery2009 · 100 citations